Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3710457 | 0.82 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL6729088 | 0.81 | TP53 (0.33) | — | |
| SCHEMBL28785662 | 0.81 | — | — | |
| Ammonia Solution, Strong SCHEMBL1896974 | 0.79 | TP53 (0.32) | — | |
| SCHEMBL3336089 | 0.75 | LMNA (0.30) | — | |
| SCHEMBL27711944 | 0.75 | — | — | |
| SCHEMBL28785686 | 0.75 | MEN1 (0.31) | — | |
| SCHEMBL6336329 | 0.73 | — | — | |
| SCHEMBL25381775 | 0.72 | MEN1 (0.31) | — | |
| SCHEMBL7806302 | 0.72 | TP53 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389187-A4 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | RANBAXY LAB LTD (IN) | 2005-03-16 | — | — | EP | claimed |
| US-20050020561-A1 | Process for the preparation of cefpodoxime acid | RANBAXY LABORATORIES LIMITED (IN) | 2005-01-27 | — | — | US | claimed |
| EP-1389187-A2 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | Ranbaxy Laboratories Limited (IN) | 2004-02-18 | — | — | EP | claimed |
| WO-2002083634-A2 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | RANBAXY LABORATORIES LIMITED (IN) | 2002-10-24 | — | — | WO | claimed |
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-105801489-B | Cycloalkyl-substituted imidazole derivatives | 第一三共株式会社 | 2019-12-10 | — | — | CN | disclosed |
| CN-105801489-A | Cycloalkyl-substituted imidazole derivative | 第三共株式会社 | 2016-07-27 | — | — | CN | disclosed |
| WO-2010097675-A1 | AN IMPROVED PREPARATION PROCESS FOR CEFPODOXIME PROXETIL | DHANUKA LABORATORIES LTD. (IN) | 2010-09-02 | — | — | WO | disclosed |
| EP-1590353-B1 | A PROCESS FOR THE PREPARATION OF CEFPODOXIME PROXETIL | LUPIN LTD (IN) | 2007-10-10 | — | — | EP | disclosed |
| US-7238812-B2 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEJI SEIKA KAISHA, LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20060293296-A1 | Process for the preparation of cefpodoxime procetil | LUPIN LIMITED (IN) | 2006-12-28 | — | — | US | disclosed |
| US-20060149055-A1 | Process for the manufacture of cefpodoxime proxetil | LUPIN LIMITED (IN) | 2006-07-06 | — | — | US | disclosed |
| US-5741902-A | INTERMEDIATES FOR CEPHEM ANTIBACTERIAL COMPOUNDS | EISAI CO., LTD. (JP) | 1998-04-21 | — | — | US | disclosed |
| EP-0761671-A1 | Cephem derivatives | Eisai Co., Ltd. (JP) | 1997-03-12 | — | — | EP | disclosed |
| US-5604217-A | CEPHALOSPORIN ANTIBIOTICS | EISAI CO., LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| US-5587473-A | BLOCKING; CONDENSATION; DEBLOCKING | EISAI CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5563265-A | BACTERICIDES | EISAI CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| US-5559225-A | ANTIBIOTICS | EISAI CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| EP-0652220-A1 | CEPHALOSPORIN DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1995-05-10 | — | — | EP | disclosed |
| EP-0484966-A2 | 7-Acyl-3-(substituted carbamoyloxy) cephem compounds, use thereof and process for their preparation | Eisai Co., Ltd. (JP) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020561-A1 | Process for the preparation of cefpodoxime acid | CYP2F1, CYP4F11, CYP51A1 | PIK3CD 930/4885 |
| US-20060293296-A1 | Process for the preparation of cefpodoxime procetil | CYP3A43, CYP2F1, PPOX | PIK3CD 1871/4885 |
| US-20060149055-A1 | Process for the manufacture of cefpodoxime proxetil | SRR, CYP2F1, MRPL21 | PIK3CD 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.